Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG) following the company's first full quarter of ZUNVEYL® commercialization. This period saw significant early adoption in the U.S. long-term care market and a key regulatory milestone in China. ZUNVEYL has been ordered in over 300 long-term care facilities with 65% placing repeat orders. Additionally, Alpha Cognition secured its first national Medicare Part D contract, enhancing patient access. For more details, visit newsfilecorp.com/release/177020.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。